Twentyeight-Seven Therapeutics
Targeting ncRNA Modulating Proteins

Twentyeight-Seven is a biopharmaceutical company focused on developing medicines that modulate functional non-coding RNA (ncRNA) to treat cancer and other human diseases. By targeting ncRNA modulating proteins (RMPs), Twentyeight-Seven can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company’s core technology comes from its four founding scientists, all leading researchers in RNA biology and cancer from Harvard Medical School: George Daley, Richard Gregory, Frank Slack, and Piotr Sliz.


University
Dana-Farber Cancer Institute
Harvard University
Sector
Life Science
Status
Active
Initial Investment Stage
Early
Team
View Website